Cognition Therapeutics extends duration of EAP for zervimesine

Cognition Therapeutics (CGTX) has extended the duration of the expanded access program, EAP, for dementia with Lewy bodies. The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment. “The EAP has been running since June 2025 and is expected to provide us with additional long-term safety data,” stated Anthony Caggiano, MD, PhD, Cognition’s chief medical officer. “We’ve received favorable feedback during the program from participants and their care partners about their experience in this program. We implemented a strategy that reduces the amount of travel for patients to clinical sites by empowering their local physicians to conduct routine health monitoring and allowing local laboratory testing. Doctors and patients appreciate these operational aspects of the program.”